Microdialysis as a way to measure antibiotics concentration in tissues

Pharmacological Research

Volumn 111, Issue , 2016, Pages 201-207

  Marchand, Sandrine ^a,b,c   Chauzy, Alexia ^a,b   Dahyot Fizelier, Claire ^a,b,c   Couet, William ^a,b,c  

^a INSERM   (France)

^b UNIVERSITÉ DE POITIERS   (France)

^c POITIERS UNIVERSITY HOSPITAL   (France)

Author keywords

Antibiotics; Distribution; Microdialysis; Pharmacodynamics; Pharmacokinetics; Tissue

Indexed keywords

AMINOGLYCOSIDE DERIVATIVE; ANTIBIOTIC AGENT; BETA LACTAM; IMIPENEM; MEROPENEM; METRONIDAZOLE; QUINOLONE DERIVATIVE; ANTIINFECTIVE AGENT;

ANTIMICROBIAL ACTIVITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG TISSUE LEVEL; HUMAN; MICRODIALYSIS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; REVIEW; BIOLOGICAL MODEL; DRUG MONITORING; PREDICTIVE VALUE; PROCEDURES; TISSUE DISTRIBUTION;

ANTI-BACTERIAL AGENTS; DRUG MONITORING; HUMANS; MICRODIALYSIS; MODELS, BIOLOGICAL; PREDICTIVE VALUE OF TESTS; TISSUE DISTRIBUTION;

EID: 84975864668     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2016.06.001     Document Type: Review

References (59)

1. [1] Ryan, D.M., Pharmacokinetics of antibiotics in natural and experimental superficial compartments in animals and humans. J. Antimicrob. Chemother. 31:Suppl. D (1993), 1–16.
2. [2] EMEA, Points to Consider on Pharmacokinetics and Pharmacodynamics in the Development of Antibacterial Medicinal Products. 2000 wwwemeaeuint/pdfs/human/ewp/265599enpdf.
3. [3] FDA, Guidance for Industry. Developing Antimicrobial Drugs ? General Considerations for Clinical Trials. 1998 wwwfdagov/cder/guidance/2580dftpdf.
4. [4] Kearney, B.P., Aweeka, F.T., The penetration of anti-infectives into the central nervous system. Neurol. Clin. 17:4 (1999), 883–900.
5. [5] Zeitlinger, M., Muller, M., Joukhadar, C., Lung microdialysis—a powerful tool for the determination of exogenous and endogenous compounds in the lower respiratory tract (mini-review). AAPS J. 7:3 (2005), E600–E608.
6. [6] Zhanel, G.G., Dueck, M., Hoban, D.J., Vercaigne, L.M., Embil, J.M., Gin, A.S., Karlowsky, J.A., Review of macrolides and ketolides: focus on respiratory tract infections. Drugs 61:4 (2001), 443–498.
7. [7] Muller, M., Haag, O., Burgdorff, T., Georgopoulos, A., Weninger, W., Jansen, B., Stanek, G., Pehamberger, H., Agneter, E., Eichler, H.G., Characterization of peripheral-compartment kinetics of antibiotics by in vivo microdialysis in humans. Antimicrob. Agents Chemother. 40:12 (1996), 2703–2709.
8. [8] Kunin, C.M., Craig, W.A., Kornguth, M., Monson, R., Influence of binding on the pharmacologic activity of antibiotics. Ann. N. Y. Acad. Sci. 226 (1973), 214–224.
9. [9] Brunner, M., Hollenstein, U., Delacher, S., Jager, D., Schmid, R., Lackner, E., Georgopoulos, A., Eichler, H.G., Muller, M., Distribution and antimicrobial activity of ciprofloxacin in human soft tissues. Antimicrob. Agents Chemother. 43:5 (1999), 1307–1309.
10. [10] Ryan, D.M., Cars, O., Hoffstedt, B., The use of antibiotic serum levels to predict concentrations in tissues. Scand. J. Infect. Dis. 18:5 (1986), 381–388.
11. [11] Muller, M., dela Pena, A., Derendorf, H., Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: distribution in tissue. Antimicrob. Agents Chemother. 48:5 (2004), 1441–1453.
12. [12] Mouton, J.W., Theuretzbacher, U., Craig, W.A., Tulkens, P.M., Derendorf, H., Cars, O., Tissue concentrations: do we ever learn?. J. Antimicrob. Chemother. 61:2 (2008), 235–237.
13. [13] Fischman, A.J., Alpert, N.M., Babich, J.W., Rubin, R.H., The role of positron emission tomography in pharmacokinetic analysis. Drug Metab. Rev. 29:4 (1997), 923–956.
14. [14] Pien, H.H., Fischman, A.J., Thrall, J.H., Sorensen, A.G., Using imaging biomarkers to accelerate drug development and clinical trials. Drug Discov. Today 10:4 (2005), 259–266.
15. [15] Korting, H.C., Schafer-Korting, M., Maass, L., Klesel, N., Mutschler, E., Cefodizime in serum and skin blister fluid after single intravenous and intramuscular doses in healthy volunteers. Antimicrob. Agents Chemother. 31:11 (1987), 1822–1825.
16. [16] Brunner, M., Schmiedberger, A., Schmid, R., Jager, D., Piegler, E., Eichler, H.G., Muller, M., Direct assessment of peripheral pharmacokinetics in humans: comparison between cantharides blister fluid sampling, in vivo microdialysis and saliva sampling. Br. J. Clin. Pharmacol. 46:5 (1998), 425–431.
17. [17] Philip-Joet, F., Bruguerolle, B., Reynaud, M., Arnaud, A., Correlations between theophylline concentrations in plasma, erythrocytes and cantharides-induced blister fluid and peak expiratory flow in asthma patients. Eur. J. Clin. Pharmacol. 43:5 (1992), 563–565.
18. [18] Stahle, L., Arner, P., Ungerstedt, U., Drug distribution studies with microdialysis. III: Extracellular concentration of caffeine in adipose tissue in man. Life Sci. 49:24 (1991), 1853–1858.
19. [19] Ungerstedt, U., Pycock, C., Functional correlates of dopamine neurotransmission?. Bull. Schweiz. Akad. Med. Wiss. 30:1–3 (1974), 44–55.
20. [20] Lonnroth, P., Jansson, P.A., Smith, U., A microdialysis method allowing characterization of intercellular water space in humans. Am. J. Physiol. 253:2 Pt. 1 (1987), E228–231.
21. [21] de Lange, E.C., Danhof, M., de Boer, A.G., Breimer, D.D., Methodological considerations of intracerebral microdialysis in pharmacokinetic studies on drug transport across the blood-brain barrier. Brain Res. Brain Res. Rev. 25:1 (1997), 27–49.
22. [22] de Lange, E.C., de Boer, A.G., Breimer, D.D., Methodological issues in microdialysis sampling for pharmacokinetic studies?. Adv. Drug Deliv. Rev. 45:2–3 (2000), 125–148.
23. [23] Mindermann, T., Zimmerli, W., Gratzl, O., Rifampin concentrations in various compartments of the human brain: a novel method for determining drug levels in the cerebral extracellular space. Antimicrob. Agents Chemother. 42:10 (1998), 2626–2629.
24. [24] Olson, R.J., Justice, J.B. Jr., Quantitative microdialysis under transient conditions. Anal. Chem. 65:8 (1993), 1017–1022.
25. [25] de Lange, E.C., Marchand, S., van den Berg, D., van der Sandt, I.C., de Boer, A.G., Delon, A., Bouquet, S., Couet, W., In vitro and in vivo investigations on fluoroquinolones; effects of the P-glycoprotein efflux transporter on brain distribution of sparfloxacin. Eur. J. Pharm. Sci. 12:2 (2000), 85–93.
26. [26] Bouw, M.R., Hammarlund-Udenaes, M., Methodological aspects of the use of a calibrator in vivo microdialysis-further development of the retrodialysis method. Pharm. Res. 15:11 (1998), 1673–1679.
27. [27] Marchand, S., Chenel, M., Lamarche, I., Pariat, C., Couet, W., Dose ranging pharmacokinetics and brain distribution of norfloxacin using microdialysis in rats. J. Pharm. Sci. 92:12 (2003), 2458–2465.
28. [28] Dahyot, C., Marchand, S., Bodin, M., Debeane, B., Mimoz, O., Couet, W., Application of basic pharmacokinetic concepts to analysis of microdialysis data: illustration with imipenem muscle distribution. Clin. Pharmacokinet. 47:3 (2008), 181–189.
29. [29] Marchand, S., Dahyot, C., Lamarche, I., Mimoz, O., Couet, W., Microdialysis study of imipenem distribution in skeletal muscle and lung extracellular fluids of noninfected rats. Antimicrob. Agents Chemother. 49:6 (2005), 2356–2361.
30. [30] Tegeder, I., Schmidtko, A., Brautigam, L., Kirschbaum, A., Geisslinger, G., Lotsch, J., Tissue distribution of imipenem in critically ill patients. Clin. Pharmacol. Ther. 71:5 (2002), 325–333.
31. [31] Herkner, H., Muller, M.R., Kreischitz, N., Mayer, B.X., Frossard, M., Joukhadar, C., Klein, N., Lackner, E., Muller, M., Closed-chest microdialysis to measure antibiotic penetration into human lung tissue. Am. J. Respir. Crit. Care Med. 165:2 (2002), 273–276.
32. [32] Karjagin, J., Lefeuvre, S., Oselin, K., Kipper, K., Marchand, S., Tikkerberi, A., Starkopf, J., Couet, W., Sawchuk, R.J., Pharmacokinetics of meropenem determined by microdialysis in the peritoneal fluid of patients with severe peritonitis associated with septic shock. Clin. Pharmacol. Ther. 83:3 (2008), 452–459.
33. [33] Chenel, M., Marchand, S., Dupuis, A., Lamarche, I., Paquereau, J., Pariat, C., Couet, W., Simultaneous central nervous system distribution and pharmacokinetic-pharmacodynamic modelling of the electroencephalogram effect of norfloxacin administered at a convulsant dose in rats. Br. J. Pharmacol. 142:2 (2004), 323–330.
34. [34] Dahyot-Fizelier, C., Lefeuvre, S., Laksiri, L., Marchand, S., Sawchuk, R.J., Couet, W., Mimoz, O., Kinetics of imipenem distribution into the peritoneal fluid of patients with severe peritonitis studied by microdialysis. Clin. Pharmacokinet. 49:5 (2010), 323–334.
35. [35] Dahyot-Fizelier, C., Frasca, D., Gregoire, N., Adier, C., Mimoz, O., Debaene, B., Couet, W., Marchand, S., Microdialysis study of cefotaxime cerebral distribution in patients with acute brain injury. Antimicrob. Agents Chemother. 57:6 (2013), 2738–2742.
36. [36] Brunner, M., Derendorf, H., Clinical microdialysis: current applications and potential use in drug development. Trends Anal. Chem. 25:7 (2006), 674–680.
37. [37] Chaurasia, C.S., In vivo microdialysis sampling: theory and applications. Biomed. Chromatogr. 13:5 (1999), 317–332.
38. [38] Li, Y., Peris, J., Zhong, L., Derendorf, H., Microdialysis as a tool in local pharmacodynamics. AAPS J. 08:02 (2006), 1–33.
39. [39] Matzneller, P., Gobin, P., Lackner, E., Zeitlinger, M., Feasibility of microdialysis for determination of protein binding and target site pharmacokinetics of colistin in vivo. J. Clin. Pharmacol. 55:4 (2015), 431–437.
40. [40] Li, Y., Peris, J., Zhong, L., Derendorf, H., Microdialysis as a tool in local pharmacodynamics. AAPS J. 8:2 (2006), E222–235.
41. [41] Schmidt, S., Banks, R., Kumar, V., Rand, K.H., Derendorf, H., Clinical microdialysis in skin and soft tissues: an update. J. Clin. Pharmacol. 48:3 (2008), 351–364.
42. [42] Brunner, M., Langer, O., Microdialysis versus other techniques for the clinical assessment of in vivo tissue drug distribution. AAPS J. 8:2 (2006), E263–271.
43. [43] Sahre, M., Naik, R., Derendorf, H., Applications of microdialysis in skin and soft tissues. Tsai, T.-H., (eds.) Applications of Microdialysis in Pharmaceutical Sciences, first ed., 2011, Wiley, 584.
44. [44] Muller, M., dela Pena, A., Derendorf, H., Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: distribution in tissue. Antimicrob. Agents Chemother. 48:5 (2004), 1441–1453.
45. [45] Gonzalez, D., Conrado, D.J., Theuretzbacher, U., Derendorf, H., The effect of critical illness on drug distribution. Curr. Pharm. Biotechnol. 12:12 (2011), 2030–2036.
46. [46] Craig, W.A., Suh, B., Changes in protein binding during disease. Scand. J. Infect. Dis.(Suppl. (14)), 1978, 239–244.
47. [47] Roberts, J.A., Lipman, J., Pharmacokinetic issues for antibiotics in the critically ill patient. Crit. Care Med. 37:3 (2009), 840–851 (quiz 859.).
48. [48] Rowland, M., Tozer, T.M., Clinical Pharmacokinetics: Concepts and Applications. 4th ed., 2011, Wolters Klumer Heath/Lippincott William & Wilkins, Philadelphia, Pa.
49. [49] Marchand, S., Chenel, M., Lamarche, I., Couet, W., Pharmacokinetic modeling of free amoxicillin concentrations in rat muscle extracellular fluids determined by microdialysis. Antimicrob. Agents Chemother. 49:9 (2005), 3702–3706.
50. [50] Hammarlund-Udenaes, M., Paalzow, L.K., de Lange, E.C., Drug equilibration across the blood-brain barrier-pharmacokinetic considerations based on the microdialysis method. Pharm. Res. 14:2 (1997), 128–134.
51. [51] Dahyot-Fizelier, C., Timofeev, I., Marchand, S., Hutchinson, P., Debaene, B., Menon, D., Mimoz, O., Gupta, A., Couet, W., Brain microdialysis study of meropenem in two patients with acute brain injury. Antimicrob. Agents Chemother. 54:8 (2010), 3502–3504.
52. [52] Akanuma, S., Uchida, Y., Ohtsuki, S., Kamiie, J., Tachikawa, M., Terasaki, T., Hosoya, K., Molecular-weight-dependent, anionic-substrate-preferential transport of beta-lactam antibiotics via multidrug resistance-associated protein 4. Drug Metab. Pharmacokinet. 26:6 (2011), 602–611.
53. [53] Spector, R., Nature and consequences of mammalian brain and CSF efflux transporters: four decades of progress. J. Neurochem. 112:1 (2010), 13–23.
54. [54] Shen, H., Ocheltree, S.M., Hu, Y., Keep, R.F., Smith, D.E., Impact of genetic knockout of PEPT2 on cefadroxil pharmacokinetics, renal tubular reabsorption, and brain penetration in mice. Drug Metab. Dispos. 35:7 (2007), 1209–1216.
55. [55] Frasca, D., Dahyot-Fizelier, C., Adier, C., Mimoz, O., Debaene, B., Couet, W., Marchand, S., Metronidazole and hydroxymetronidazole central nervous system distribution: 1. microdialysis assessment of brain extracellular fluid concentrations in patients with acute brain injury. Antimicrob. Agents Chemother. 58:2 (2014), 1019–1023.
56. [56] Schmidt, S., Rock, K., Sahre, M., Burkhardt, O., Brunner, M., Lobmeyer, M.T., Derendorf, H., Effect of protein binding on the pharmacological activity of highly bound antibiotics. Antimicrob. Agents Chemother. 52:11 (2008), 3994–4000.
57. [57] Adembri, C., Novelli, A., Pharmacokinetic and pharmacodynamic parameters of antimicrobials: potential for providing dosing regimens that are less vulnerable to resistance. Clin. Pharmacokinet. 48:8 (2009), 517–528.
58. [58] Bradley, J.S., Garonzik, S.M., Forrest, A., Bhavnani, S.M., Pharmacokinetics, pharmacodynamics, and Monte Carlo simulation: selecting the best antimicrobial dose to treat an infection. Pediatr. Infect. Dis. J. 29:11 (2010), 1043–1046.
59. [59] Brunner, M., Derendorf, H., Muller, M., Microdialysis for in vivo pharmacokinetic/pharmacodynamic characterization of anti-infective drugs. Curr. Opin. Pharmacol. 5:5 (2005), 495–499.